TWI821163B - 可分散組成物 - Google Patents

可分散組成物 Download PDF

Info

Publication number
TWI821163B
TWI821163B TW106136552A TW106136552A TWI821163B TW I821163 B TWI821163 B TW I821163B TW 106136552 A TW106136552 A TW 106136552A TW 106136552 A TW106136552 A TW 106136552A TW I821163 B TWI821163 B TW I821163B
Authority
TW
Taiwan
Prior art keywords
dispersible tablet
fraction
diluent
composition
peg
Prior art date
Application number
TW106136552A
Other languages
English (en)
Chinese (zh)
Other versions
TW201828927A (zh
Inventor
哈沙德 帕坦卡
尼可拉斯 高瓦特斯
戈帕爾 藍格拉強
Original Assignee
愛爾蘭商健生科學愛爾蘭無限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 愛爾蘭商健生科學愛爾蘭無限公司 filed Critical 愛爾蘭商健生科學愛爾蘭無限公司
Publication of TW201828927A publication Critical patent/TW201828927A/zh
Application granted granted Critical
Publication of TWI821163B publication Critical patent/TWI821163B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW106136552A 2016-10-24 2017-10-24 可分散組成物 TWI821163B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621036404 2016-10-24
IN201621036404 2016-10-24

Publications (2)

Publication Number Publication Date
TW201828927A TW201828927A (zh) 2018-08-16
TWI821163B true TWI821163B (zh) 2023-11-11

Family

ID=60262899

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106136552A TWI821163B (zh) 2016-10-24 2017-10-24 可分散組成物

Country Status (21)

Country Link
US (2) US11065198B2 (enExample)
EP (2) EP3528791B1 (enExample)
JP (2) JP7197474B2 (enExample)
KR (2) KR20190073450A (enExample)
CN (1) CN110191704A (enExample)
CA (1) CA3039562A1 (enExample)
DK (1) DK3528791T3 (enExample)
ES (1) ES2970870T3 (enExample)
FI (1) FI3528791T3 (enExample)
HR (1) HRP20240118T1 (enExample)
HU (1) HUE064823T2 (enExample)
LT (1) LT3528791T (enExample)
MA (1) MA46563B1 (enExample)
MX (1) MX2019004767A (enExample)
PL (1) PL3528791T3 (enExample)
PT (1) PT3528791T (enExample)
RS (1) RS65159B1 (enExample)
SI (1) SI3528791T1 (enExample)
SM (1) SMT202400060T1 (enExample)
TW (1) TWI821163B (enExample)
WO (1) WO2018077815A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine
WO2021104487A1 (en) 2019-11-29 2021-06-03 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
GB202211231D0 (en) * 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101056673A (zh) * 2004-09-02 2007-10-17 詹森药业有限公司 4－[[4－[[4－(2－氰基乙烯基)－2,6－二甲基苯基]氨基]－2－嘧啶基]氨基]苄腈的盐酸盐
WO2015136294A1 (en) * 2014-03-13 2015-09-17 Cipla Limited Pharmaceutical composittion comprising rilpivirine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181966A1 (en) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Compression-coated dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7399856B2 (en) 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PT1632232E (pt) 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
PT3366278T (pt) 2006-06-23 2024-10-21 Janssen Sciences Ireland Unlimited Co Suspensões aquosas de tmc278
EP3102188A4 (en) * 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
AU2015258836B2 (en) * 2014-05-16 2020-07-16 Vivus, Inc. Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101056673A (zh) * 2004-09-02 2007-10-17 詹森药业有限公司 4－[[4－[[4－(2－氰基乙烯基)－2,6－二甲基苯基]氨基]－2－嘧啶基]氨基]苄腈的盐酸盐
WO2015136294A1 (en) * 2014-03-13 2015-09-17 Cipla Limited Pharmaceutical composittion comprising rilpivirine

Also Published As

Publication number Publication date
US20220008333A1 (en) 2022-01-13
MA46563A (fr) 2019-08-28
RU2019115672A (ru) 2020-11-24
RS65159B1 (sr) 2024-02-29
SI3528791T1 (sl) 2024-04-30
TW201828927A (zh) 2018-08-16
KR102861006B1 (ko) 2025-09-16
US11065198B2 (en) 2021-07-20
EP3528791B1 (en) 2023-12-06
ES2970870T3 (es) 2024-05-31
JP2020500168A (ja) 2020-01-09
JP7197474B2 (ja) 2022-12-27
SMT202400060T1 (it) 2024-03-13
PT3528791T (pt) 2024-02-19
EP4248947A2 (en) 2023-09-27
JP2023011659A (ja) 2023-01-24
MA46563B1 (fr) 2024-01-31
MX2019004767A (es) 2019-07-01
EP4248947A3 (en) 2023-11-22
CA3039562A1 (en) 2018-05-03
HRP20240118T1 (hr) 2024-04-12
KR20190073450A (ko) 2019-06-26
US20200069579A1 (en) 2020-03-05
LT3528791T (lt) 2024-05-27
BR112019007564A2 (pt) 2019-07-02
PL3528791T3 (pl) 2024-04-02
EP3528791A1 (en) 2019-08-28
WO2018077815A1 (en) 2018-05-03
HUE064823T2 (hu) 2024-04-28
RU2019115672A3 (enExample) 2021-01-21
DK3528791T3 (da) 2024-01-29
CN110191704A (zh) 2019-08-30
KR20240011873A (ko) 2024-01-26
FI3528791T3 (fi) 2024-01-30

Similar Documents

Publication Publication Date Title
AU2021204135B2 (en) Dispersible compositions
JP2023011659A (ja) 分散性組成物
HK40101645A (en) Dispersible compositions
RU2826218C2 (ru) Диспергируемые композиции
HK40013979B (en) Dispersible compositions
HK40013979A (en) Dispersible compositions
HK40013937A (en) Dispersible compositions
CN101068597B (zh) 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
HK40069676A (en) Dispersible compositions
CA2973301C (en) Dispersible compositions comprising bedaquiline fumarate
BR112019007564B1 (pt) Composições dispersíveis, seu processo de fabricação e uso de rilpivirina
OA18325A (en) Dispersible compositions
EA042247B1 (ru) Диспергируемые композиции